Atorvastatin

InterventionStatins5 papers5 findingsPubChem 60823ChEBI 39548MeSH D000069059

Human trial2
Humans1
Cells1

Outcomes

4

Endoglin

downin humans1

1 study

Atorvastatin decreases endoglin in humans.
“Atorvastatin and rosuvastatin therapies significantly decreased plasma concentrations of both endocan and endoglin”
Humansprimary cardiovascular preventionplasmaup to 16 weeksfemales
The Influence of Statin Therapy on Markers of Endothelial Dysfunction, Endocan and Endoglin, in Postmenopausal Women-A Prospective Study · Biomedicines · 27 Aug 2026

Endocan

downin humans1

1 study

Atorvastatin decreases endocan in humans.
“Atorvastatin and rosuvastatin therapies significantly decreased plasma concentrations of both endocan and endoglin”
Humansprimary cardiovascular preventionplasmaup to 16 weeksfemales
The Influence of Statin Therapy on Markers of Endothelial Dysfunction, Endocan and Endoglin, in Postmenopausal Women-A Prospective Study · Biomedicines · 27 Aug 2026

Major adverse cardiovascular events

no changein humans1

1 study

Atorvastatin has no effect on major adverse cardiovascular events in humans.
Human trialnoncardiac surgery in patients with RCRI >= 180 mg24 hours preoperatively
The Effect of High-Dose Atorvastatin on Postoperative Troponin in Patients Undergoing Non-Cardiac Surgery: A Triple-Blind Randomized Clinical Trial · Research in heart yield and translational medicine · 1 Jan 2025

High-sensitivity cardiac troponin

downin humans1

1 study

Atorvastatin decreases high-sensitivity cardiac troponin in humans.
Human trialnoncardiac surgery in patients with RCRI >= 180 mg24 hours preoperatively
The Effect of High-Dose Atorvastatin on Postoperative Troponin in Patients Undergoing Non-Cardiac Surgery: A Triple-Blind Randomized Clinical Trial · Research in heart yield and translational medicine · 1 Jan 2025

High-sensitivity cardiac troponin →

Associations

1

Type 2 diabetes

upin humans1

1 study

Atorvastatin raises the risk of type 2 diabetes in humans.
Reviewdose- and susceptibility-dependent
Atorvastatin Safety Reappraised: From Pharmacogenomic Mechanisms to Personalized Risk Management · Cardiovascular therapeutics · 1 Jan 2026

Type 2 diabetes →

Latest

4

Cardiovascular TherapeuticsReviewYesterday

Atorvastatin Safety Reappraised: From Pharmacogenomic Mechanisms to Personalized Risk Management

JACC Basic to Translational ScienceCells29 Sep

Rates of Lipoprotein(a) Oxidation Accelerate at Elevated Levels and Attenuate With Atorvastatin Active Metabolites Compared With Other Statins

Research in Heart Yield and Translational MedicineHuman trial28 Sep

The Effect of High-Dose Atorvastatin on Postoperative Troponin in Patients Undergoing Non-Cardiac Surgery: A Triple-Blind Randomized Clinical Trial

HealthcareHumans26 Sep

Generic Versus Branded Atorvastatin: A Single-Center Comparative Analysis of Clinical Effectiveness and Post-Delisting Cost Savings in Saudi Arabia

BiomedicinesHuman trial26 Sep

The Influence of Statin Therapy on Markers of Endothelial Dysfunction, Endocan and Endoglin, in Postmenopausal Women-A Prospective Study